Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical innovator developing targeted therapies for oncology and rare diseases through advanced protein engineering. This dedicated news hub provides investors and industry observers with comprehensive access to official corporate communications and verified developments.
Our curated collection features INBX's latest press releases, regulatory filings, and clinical trial updates. Track progress across therapeutic programs including multivalent biologics and optimized antibody candidates designed through the company's proprietary modular platforms. Stay informed about strategic partnerships, research milestones, and financial disclosures that shape INBX's position in biopharmaceutical innovation.
Key updates include clinical development timelines, intellectual property advancements, and collaborative research initiatives. All content is sourced directly from company filings and authorized statements to ensure reliability. Bookmark this page for streamlined access to INBX's evolving pipeline and corporate announcements, presented with neutral analysis suitable for both institutional and individual investors.
Inhibrx, Inc. (Nasdaq: INBX) announced initial results from Part 3 of a Phase 1 trial of INBRX-106, a hexavalent OX40 agonist combined with Keytruda®, for treating solid tumors. 21 patients participated, with a maximum tolerated dose identified at 0.1 mg/kg. Initial findings indicated two durable partial responses and tumor volume reductions in additional cases. The trial also highlighted the notable tolerability of the combination therapy. Inhibrx expressed optimism regarding the clinical translatability of preclinical data.
Inhibrx, Inc. (Nasdaq: INBX) announced the FDA has granted orphan-drug designation for INBRX-109, targeting metastatic chondrosarcoma, a rare bone cancer with no approved therapies. This designation offers financial incentives for clinical development and up to seven years of market exclusivity. Preliminary results from a Phase 1 trial show disease control in 89% of evaluable patients and a median progression-free survival of 7.4 months. The company is advancing its Phase 2 trial aiming for registration. Inhibrx's strategy focuses on innovative therapies for oncology and orphan diseases.
Inhibrx, Inc. (Nasdaq: INBX) reported a net loss of $20.6 million for Q3 2021, equating to $0.54 per share, a slight decrease from $20.5 million in the same quarter last year. Total revenue for Q3 was $2.5 million, down from $5.9 million year-over-year. Cash and cash equivalents increased to $141.1 million as of November 9, 2021, from $112.7 million at the end of Q3. The company announced interim Phase 1 trial results for INBRX-101, showing potential to normalize AAT levels in patients with AAT deficiency, and appointed key executives to bolster its operations.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the Society for Immunotherapy of Cancer's annual meeting from November 10-14, 2021, presenting three posters on its clinical candidates. The presentations include data on INBRX-105 and INBRX-106, focusing on pharmacodynamic biomarkers and anti-tumor activity. Additionally, the emerging candidate INBRX-121 will be introduced, targeting NK cells to enhance cytotoxicity. These highlights reflect Inhibrx's ongoing commitment to advancing oncology therapeutics.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the CTOS 2021 Virtual Annual Meeting from November 10-13, 2021. The company will present findings on its drug candidate, INBRX-109, focused on conventional chondrosarcoma and Ewing sarcoma. Presentations include an oral update on safety and efficacy on November 11, and a poster detailing cohort expansion plans. Inhibrx will also participate in multiple upcoming investor conferences in November and December. These presentations are expected to bolster investor confidence and showcase advancements in their oncology pipeline.
On October 28, 2021, Inhibrx (Nasdaq: INBX) announced the appointment of three key executives: David Matly as Chief Commercial Officer, David Kao as Vice President of Regulatory Affairs, and Jack Tsai as Vice President of Business Development. These strategic hires aim to enhance the company's clinical pipeline focused on areas with high unmet medical need, such as Alpha-1 Antitrypsin Deficiency and Chondrosarcoma. Additionally, Kristiina Vuori joined the Board of Directors, taking over from Brendan Eckelman, who stepped down but continues to lead research strategy.
Inhibrx, Inc. (Nasdaq: INBX) announced interim results from a Phase 1 clinical trial for INBRX-101, a recombinant human AAT-Fc fusion protein aimed at treating alpha-1 antitrypsin deficiency (AATD). The study involved 21 patients with no severe adverse events reported, and only mild to moderate drug-related effects. Dose-dependent increases in AAT levels were observed, with promising results indicating the potential for monthly dosing compared to the current standard of care requiring 52 infusions annually. Further data from multiple ascending doses is expected in early 2022.
Inhibrx, Inc. (Nasdaq: INBX) will host a live webcast on October 12, 2021, at 5:30 a.m. PT to present interim results from its Phase 1 clinical trial of INBRX-101, a treatment for alpha-1 antitrypsin deficiency (AATD). AATD affects approximately 100,000 patients in the U.S. and leads to severe lung function loss. INBRX-101 is designed for monthly dosing, addressing shortcomings of current weekly plasma-derived treatments. Further details and results will be available on Inhibrx's website following the presentation.
Inhibrx, a clinical-stage biotechnology company (NASDAQ: INBX), announced its participation in the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 8:40 a.m. Pacific Time. This virtual presentation will showcase its novel biologic therapeutic candidates in oncology and orphan diseases, utilizing its proprietary sdAb platform. Attendees can access the live webcast through Inhibrx's investor website, which will remain available for 60 days post-event. The company collaborates with major biotech firms, enhancing its research capabilities.
Inhibrx, Inc. (Nasdaq: INBX) reported its financial results for Q2 2021, showing cash and cash equivalents of $125.7 million, a slight decrease from $128.7 million at year-end 2020. R&D expenses decreased to $17.9 million, down from $19.0 million in Q2 2020, while G&A expenses rose to $2.9 million from $1.5 million. The company recorded a net loss of $20.7 million ($0.55 per share), compared to a net loss of $17.9 million ($0.99 per share) in the same quarter last year. The financial report reflects ongoing development in its clinical programs.
